RxDoctor Payments Data

Sadananda Hegde, MD

Cardiovascular Disease · Lumberton, NCNPI 1083611586

Payments from drug & device makers

$389in general payments, 2019–2025

Across 9 payments — averaging $43.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$115
  • Abiomed$113
  • Inari Medical, Inc.$57
  • GSK$34
  • Irhythm Technologies, Inc.$22
  • Novo Nordisk$18
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$389100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$389 in reported general payments places this provider in the 20th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$76,900
Medicare patients
206
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$76,345
JardianceEmpagliflozin34$37,716
XareltoRivaroxaban18$17,942
OzempicSemaglutide12$11,047
LinzessLinaclotide15$9,998
Soliqua 100-33Insulin Glargine/Lixisenatide16$8,835
Synjardy XrEmpagliflozin/Metformin Hcl13$7,637
Atorvastatin Calcium309$4,200
Amlodipine Besylate426$2,973
Ezetimibe130$2,731
Losartan Potassium257$2,536
Potassium Chloride95$2,205
Gabapentin98$1,590
Metoprolol Succinate144$1,525
Rosuvastatin Calcium161$1,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$18$45,35347 claims
Novo NordiskOzempic$18$11,04712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Lumberton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →